PD-1/PD-L1抑制剂在HIV/AIDS合并癌症患者中的应用进展

Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer

摘要: 目前免疫治疗已经成为癌症治疗的常见手段之一，其中PD-1/PD-L1抑制剂疗效显著。癌症及各种机会性感染是艾滋病患者常见的并发症。因该类患者的特殊免疫情况，多数癌症免疫治疗临床试验中，艾滋病作为一项排除标准，使免疫治疗在该类感染者中寸步难行。而高效抗反转录病毒治疗的普及使艾滋病感染者寿命不断延长，因而寻找免疫治疗在艾滋病合并癌症患者中的机遇迫在眉睫。

Abstract: Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS. Owing to the special immune situation of these patients, AIDS is regarded as an exclusion standard in most clinical trials for cancer immunotherapy, conferring immunotherapy difficulty in treating patients with AIDS. The popularity of effective antiretroviral drugs has prolonged the lifetime of people with AIDS. Therefore, exploiting the opportunity of using immunotherapy in AIDS with cancer is urgent.